Khosravan Reza, Grabowski Brian, Wu Jing-Tao, Joseph-Ridge Nancy, Vernillet Laurent
TAP Pharmaceuticals Products Inc., Lake Forest, IL, USA.
Br J Clin Pharmacol. 2008 Mar;65(3):355-63. doi: 10.1111/j.1365-2125.2007.03016.x. Epub 2007 Oct 22.
What is already known about this subject. Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase. What this study adds. This is the first manuscript to address the effect of food and antacid on the pharmacokinetics and/or pharmacodynamics of febuxostat. The study will determine whether the drug can be administered regardless of food or antacid. It will therefore influence how the drug should be administered.
To evaluate the effects of food or antacid on the pharmacokinetics and/or pharmacodynamics of febuxostat.
Four Phase I, two-period, crossover studies were performed in healthy male and female subjects. Subjects either received single 40-mg (n = 24), multiple 80-mg (n = 24) and single 120-mg (n = 20) doses of febuxostat in fasting and nonfasting conditions, or received single 80-mg (n = 24) doses alone or with antacid.
Food caused a decrease in C(max) (38-49%) and AUC (16-19%) of febuxostat at different dose levels following single or multiple oral dosing with febuxostat. However, a slightly greater percent decrease in serum uric acid concentrations (58% vs. 51%) after multiple dosing with 80 mg of febuxostat under nonfasting conditions was observed, which was statistically (P < 0.05) but not clinically significant. Antacid caused a decrease in C(max) (32%), but had no effect on AUC of febuxostat. Febuxostat was safe and well tolerated in all studies.
Even though food caused a decrease in the rate and extent of absorption of febuxostat, this decrease was not associated with a clinically significant change in febuxostat pharmacodynamic effect. Despite a decrease in the absorption rate of febuxostat, antacid had no effect on the extent of febuxostat absorption. Therefore, febuxostat can be administered regardless of food or antacid intake.
关于该主题已有的认知。非布索坦是一种新型的非嘌呤类黄嘌呤氧化酶选择性抑制剂。本研究的新增内容。这是首篇探讨食物和抗酸剂对非布索坦药代动力学和/或药效学影响的手稿。该研究将确定无论是否进食或服用抗酸剂,该药是否都能给药。因此,这将影响该药的给药方式。
评估食物或抗酸剂对非布索坦药代动力学和/或药效学的影响。
在健康男性和女性受试者中进行了四项I期、两阶段、交叉研究。受试者分别在禁食和非禁食条件下接受单次40毫克(n = 24)、多次80毫克(n = 24)和单次120毫克(n = 20)剂量的非布索坦,或单独接受单次80毫克(n = 24)剂量或与抗酸剂一起服用。
在单次或多次口服非布索坦后,不同剂量水平下,食物导致非布索坦的Cmax(38 - 49%)和AUC(16 - 19%)降低。然而,在非禁食条件下多次服用80毫克非布索坦后,观察到血清尿酸浓度的降低百分比略高(58%对51%),这在统计学上具有显著性(P < 0.05),但在临床上无显著意义。抗酸剂导致Cmax降低(32%),但对非布索坦的AUC无影响。在所有研究中,非布索坦安全且耐受性良好。
尽管食物会导致非布索坦的吸收速率和程度降低,但这种降低与非布索坦药效学效应的临床显著变化无关。尽管非布索坦的吸收速率降低,但抗酸剂对非布索坦的吸收程度无影响。因此,无论是否进食或服用抗酸剂,均可服用非布索坦。